ASX:PYC

PYC Therapeutics Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive PYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PYC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About PYC Therapeutics

PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:PYC
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: pyctx.com
Phone: 61 8 6151 0992
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $3.07 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: A$0.02 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 1.35
Current Ratio: 15.71
Quick Ratio: 15.68

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for PYC Therapeutics.

0.0 Community Rank

Outperform Votes
PYC Therapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
PYC Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about PYC Therapeutics and other stocks. Vote “Outperform” if you believe PYC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PYC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
PYC Therapeutics does not currently pay a dividend.
Dividend Growth
PYC Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PYC Therapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

PYC Therapeutics (ASX:PYC) Frequently Asked Questions

What stocks does MarketBeat like better than PYC Therapeutics?: Wall Street analysts have given PYC Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PYC Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are PYC Therapeutics' key executives?: PYC Therapeutics' management team includes the following people:
Dr. Rohan Hockings MBBS, MBBS (Hons.), J.D., G.D.L.P, CEO & Director (Age 38, Pay $395k)
Mr. Kevin Ronald Hart B.Com., F.C.A., B.Comm (Hons), FCA, Company Sec. & CFO (Age 59)
Prof. Sue Fletcher, Chief Scientific Officer
Mr. Sahm Nasseri M.B.A., MBA, CEO of US operations & Director (Age 37)
Mr. Kaggen Ausma L.L.B., Chief Bus. Officer
Dr. May Orfali, Chief Medical Officer of US Operations
Dr. Glenn Noronha, Chief Devel. Officer (Age 56)
Who are some of PYC Therapeutics' key competitors?: Some companies that are related to PYC Therapeutics include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of PYC's competitors.
What is PYC Therapeutics' stock symbol?: PYC Therapeutics trades on the ASX under the ticker symbol "PYC."
How much money does PYC Therapeutics make?: PYC Therapeutics has a market capitalization of $0.00 and generates $3.07 million in revenue each year.
What is PYC Therapeutics' official website?: The official website for PYC Therapeutics is pyctx.com.
How can I contact PYC Therapeutics?: The company can be reached via phone at 61 8 6151 0992.

This page was last updated on 10/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.